Associated Papers
Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK.
Tran KB et al.
Bmc Cancer, 2021
33549048 (PubMed )
Supplement: 12885_2021_7826_MOESM6_ESM.xlsx › Sheet1
Select a paper to view details